ClinicalTrials.gg

Hypertension, Pulmonary clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,092 studies for Hypertension, Pulmonary across more than 10 countries. 244 are recruiting or about to start. 635 of them are mainly about Hypertension, Pulmonary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 4 narrower conditions too, such as Pulmonary Arterial Hypertension: 1,685 studies, 372 open.

ClinicalTrials.gov finds 2,100 studies for Hypertension, Pulmonary. How that becomes 1,092 here

This page counts the studies the registry files under Hypertension, Pulmonary, and those it files under no condition that list Hypertension, Pulmonarythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,100Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −591Filed under a narrower condition, counted on its own pagePulmonary Arterial Hypertension 507 · Cirrhosis, Familial, with Pulmonary Hypertension 37 · Persistent Fetal Circulation Syndrome 33 · Pulmonary edema of mountaineers 8
  3. −52List Hypertension, Pulmonary as a condition, but the registry did not file them under itMost often written as “Chronic Thromboembolic Pulmonary Hypertension” (19), “Pulmonary Hypertension of Newborn” (4), and “Persistent Pulmonary Hypertension” (3). The registry filed them under other conditions only, most often Heart Failure (8) and Pulmonary Embolism (8).
  4. −365Match it another way69 name it in the title, 7 in a keyword, and 289 by a synonym or other text the search reads.
  5. 1,092The count on this page73 of them list Hypertension, Pulmonary in their own words; the registry filed them under no condition.

Status

Completed
517
Recruiting
164
Status unknown
125
Terminated
120
Not yet recruiting
62
Withdrawn
49

Phase

Phase 2
191
Phase 3
142
Phase 4
76
Phase 1
71
Early Phase 1
13

Where

United States
397
Germany
150
United Kingdom
117
France
108
Canada
94
China
85

Who develops what

Add Hypertension, Pulmonary to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 15 companies, 11 with this as their studies’ main aim; 5 with a live phase 3 study; 3 primary completions in the next 12 months. Compare GNI Group, Insmed and Merck here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
treprostinil hexadecyl ester☆ Track2 live phase-3 studies: NCT07234032, NCT07179380Insmed Incorporated
mosliciguat☆ Track1 live phase-3 study: NCT07816185Pulmovant, Inc.
treprostinilApproved: US · EU 2020☆ Track1 live phase-3 study: NCT07285655Liquidia Technologies, Inc.
sotaterceptApproved: EU 2024☆ Track1 live phase-3 study: NCT07839585Merck & Co., Inc
treprostinilApproved: US · EU 2020☆ Track1 live phase-3 study: NCT07923526United Therapeutics

The 5 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.mosliciguat · Pulmovant, Inc. · Phase 2 main aimNCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD — primary endpoint: Incidence and nature of participant TEAEs, SAEs, and AEs leading to discontinuation · 20 enrolled
  • Mar 2027 est.ROC-101 · AllRock Bio, Inc. · Phase 2 named, not the main aimNCT07175038 A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) — primary endpoint: Change in Pulmonary Vascular Resistance (PVR) from Baseline versus at 24 weeks · 40 enrolled
  • 30 Aug 2027 est.APL-9796 · Apollo Therapeutics Ltd · Phase 2 named, not the main aimNCT06846554 A Trial of "APL-9796'' in Adults With Pulmonary Hypertension — primary endpoint: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] · 48 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hypertension, Pulmonary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here PDE5 inhibitors 4 open · Endothelin receptor antagonists 1 open · Bronchodilators 1 open · Diuretics 9 · Tyrosine kinase inhibitors (TKIs) 6

Coming up

68studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger. 39 (24%) take children under 18. 3 (2%) are for women only and 0 (0%) for men only; 24 (15%) take healthy volunteers.

Recruiting studies that take each age, of 164
AgeWomenMen
1027 (16%)27 (16%)
18146 (89%)143 (87%)
30147 (90%)144 (88%)
40152 (93%)149 (91%)
50152 (93%)149 (91%)
65148 (90%)147 (90%)
75145 (88%)144 (88%)
85123 (75%)122 (74%)

Across all 1,092 studies, recruiting or not: 23% stop at 75 or younger and 14% at 65; 22% take children; 1% are for women only and 1% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hypertension, Pulmonary studies take

Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 119 mo15–39 · 21 studies——
Phase 244 mo25–71 · 50 studies——
Phase 352 mo30–83 · 31 studies——
Phase 442 mo21–54 · 23 studies——
Interventional, no phase23 mo9–48 · 150 studies—20 mo9–46 · 135 studies
Observational59 mo24–107 · 167 studies—60 mo24–167 · 142 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,092. Browse all 1,092 → or search them.